Aphria Offers Big Upside if the Tilray Deal Closes
Aphria offers 90% upside, but this return won’t come for free
Read More»
Locked & Lit: The Grizzle Cannabis Portfolio
See how Grizzle invests in the emerging cannabis industry. Our proprietary portfolio revealed.
Read More»
Why Curaleaf Chairman Boris Jordan is Building Value Not Cashing Out
An interview filled with insights from the chairman of the largest cannabis company in North America
Read More»WITH CHRISTOPHER WOOD
Internationally renowned for his salient predictions of market bubbles, Chris provides global investment insights in his weekly column 'Macro Battleship'.
Coinbase IPO Guide: Don’t Sleep on This Crypto Freight Train
The most hyped IPO of the year is finally here. Helping you decide if Coinbase is priced for perfection or a screaming buy.
Read More»
Ready Player One: The Definitive Roblox IPO Guide
Is Roblox the digital themepark of the future or just an overpriced video game company? The answer will suprise you.
Read More»
The Affirm IPO is a Bet on the Future of Peloton
Affirm will run as long as Peloton doesn’t sink it first.
Read More»
Trulieve CEO Kim Rivers Doesn’t Need Debt to Grow
Kim Rivers talks catalysts, why she doesn’t like debt and where future growth is going to come from in this exclusive interview.
Read More»
Marijuana Investor Roundup: Analysis of the Week’s Most Important Events (Apr 25th, 2020)
A weekly review of only the most important cannabis news to impact your portfolio
Read More»
Organigram Announces $49M At-The-Market Equity Program
As we feared and warned investors about earlier, the company has announced today that it is doing a at-the-market equity raise program valued at $49M.
Read More»
Copper Will be the King of the Coming Commodity Supercycle
A commodity supercycle is approaching. Learn why Copper will be the king of the commodities.
Read More»
AMC is Going Bankrupt – Can WallstreetBets Save It
AMC is going bankrupt, unless the WallStreetBets crew can save it. But will they?
Read More»
Danimer Scientific: The Bioplastic 15X Home Run
Looking for a high-growth, ESG stock? Danimer Scientific is an ESG home run.
Read More»PSYCHEDELICS
Why Compass Pathways (CMPS) is a 5-bagger: $210/share
Grizzle outlines the structural share price upside of Compass Pathways and its psilocybin drug: COMP 360 to treat depression.
Read More»
The Most Anticipated Psychedelic IPO: Compass Pathways (CMPS)
Grizzle sits down with Terry Chong (Partner, Grizzle Venture) to discuss one of the most anticipated psychedelic IPOs: Compass Pathaways
Read More»
Grizzle Twitter
AS FEATURED ON
